Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
A
00

AstraZeneca reports mixed late-stage trial results with Ultomiris failure and Claudin 18.2 ADC success

Jul 27, 2026

AstraZeneca reports mixed clinical results as its rare disease drug Ultomiris failed to achieve statistical significance in a late-stage trial for adult stem cell transplant complications. Despite this setback, which follows other recent pipeline failures in 2026, AstraZeneca's experimental gastric cancer drug sonesitatug vedotin successfully improved overall survival in a Phase III trial. The company still plans pediatric regulatory filings for Ultomiris and targets $80 billion in annual revenue by 2030.

Story comments

Loading comments…

Related Projects

AstraZeneca

Topics

Clinical trialsOncologyCancer Treatment & TherapiesDrug Policy, Pricing & ApprovalRare diseasesCancer & Oncology